- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Palvella Therapeutics Inc (PVLA)
Palvella Therapeutics Inc stock price live, this page displays NASDAQ PVLA stock exchange data. View the PVLA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Palvella Therapeutics Inc real time stock price chart below.
What Is the Palvella Therapeutics Inc Stock Price Today?
The Palvella Therapeutics Inc stock price today is 40.900.
What Is the Stock Symbol for Palvella Therapeutics Inc?
The stock symbol for Palvella Therapeutics Inc is ""PVLA.""
What Stock Exchange Does Palvella Therapeutics Inc Trade On?
Palvella Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Palvella Therapeutics Inc a Good Stock to Buy?
Determining whether Palvella Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PVLA quote. (ISIN: US6979471090)
What Is the Palvella Therapeutics Inc Stock Price Today?
The Palvella Therapeutics Inc stock price today is 40.900.
What Is the Stock Symbol for Palvella Therapeutics Inc?
The stock symbol for Palvella Therapeutics Inc is ""PVLA.""
What Stock Exchange Does Palvella Therapeutics Inc Trade On?
Palvella Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Palvella Therapeutics Inc a Good Stock to Buy?
Determining whether Palvella Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PVLA quote. (ISIN: US6979471090)
NASDAQ
Currency in USD
40.900
+1.850(+4.74%)
Closed·
After Hours
40.9000.000(0.00%)
·
Fair Value
An estimate of a Palvella Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.950
41.000
52 wk Range
11.170
41.000
PVLA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week High
1/2
Fair Value
An estimate of a Palvella Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
38.95041.000
52 wk Range
11.17041.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PVLA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Palvella Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
53.583
Upside
+31.01%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Palvella Therapeutics Inc Company Profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Palvella Therapeutics Inc Earnings Call Summary for Q1/2025
- Q1 2025 net loss of $8.2M ($0.74/share); R&D expenses up to $4.1M from $1M YoY; stock down 2.81% to $21.09
- $75.6M cash reserves provide 2-year runway; projected $30M spend in 2025; cash balance expected to remain above $55M by year-end
- Phase III trials for Qtorin Rapamycin progressing; top-line data for Microcystic Lymphatic Malformations study due Q1 2026
- Two new Qtorin programs to be announced in H2 2025; CEO emphasizes focus on rare genetic skin diseases leadership
- Stock shows 80.8% YTD return; analysts set price targets between $38-$70; company rated 'GOOD' financial health by InvestingPro
Last Updated: 15/05/2025, 14:38
Read Full TranscriptCompare PVLA to Peers and Sector
Metrics to compare | PVLA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPVLAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −19.8x | −3.0x | −0.5x | |
PEG Ratio | 0.04 | −0.06 | 0.00 | |
Price/Book | 8.1x | 2.0x | 2.6x | |
Price / LTM Sales | - | 9.5x | 3.3x | |
Upside (Analyst Target) | 22.2% | 205.7% | 43.4% | |
Fair Value Upside | Unlock | 6.6% | 7.1% | Unlock |
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 53.583
(+31.01% Upside)
Earnings
Latest Release
May 15, 2025
EPS / Forecast
-0.74 / -0.86
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Palvella Therapeutics Trade On?
Palvella Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Palvella Therapeutics?
The stock symbol for Palvella Therapeutics is "PVLA."
What Is the Palvella Therapeutics Market Cap?
As of today, Palvella Therapeutics market cap is 452.18M.
What Is Palvella Therapeutics's Earnings Per Share (TTM)?
The Palvella Therapeutics EPS (TTM) is -5.05.
From a Technical Analysis Perspective, Is PVLA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Palvella Therapeutics Stock Split?
Palvella Therapeutics has split 2 times.
How Many Employees Does Palvella Therapeutics Have?
Palvella Therapeutics has 14 employees.
What is the current trading status of Palvella Therapeutics (PVLA)?
As of 10 Aug 2025, Palvella Therapeutics (PVLA) is trading at a price of 40.90, with a previous close of 39.05. The stock has fluctuated within a day range of 38.95 to 41.00, while its 52-week range spans from 11.17 to 41.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.